Pau d'Arco
Best-in-class: Pau d'Arco
A South American bark traditionally used for antifungal (candida), immune and antimicrobial support.
Pau d'Arco quick facts
| Suggested dose | As directed (tea or extract), short courses. |
| How often | Short courses only |
| Who it's for | Candida/antifungal and immune support. |
In vitro activity is real; human evidence is essentially absent, and the isolated compounds studied pharmacologically are not what is in the tea. Lapachol at higher doses causes nausea, vomiting and anticoagulant effects — trials were abandoned partly for toxicity. Long traditional use, thin modern support, and a real bleeding interaction.
How Pau d'Arco actually works
Lapachol and beta-lapachone are naphthoquinones with antifungal, antibacterial and antiparasitic activity in vitro, and beta-lapachone has been investigated as an anticancer agent through topoisomerase inhibition. The traditional bark preparation contains far lower concentrations than the isolated compounds studied.
Where to get Pau d'Arco
Find Pau d'Arco on iHerb →What it is, why it recurs, and where this fits — free to read.
The evidence for Pau d'Arco
Graded by what exists behind each claim.
✅ Clinically validated
- Lapachol/naphthoquinones show antifungal and antimicrobial activity in studies.
- Human trials are limited; use is largely traditional.
📊 Correlative data
- Traditional South American use, and its reputation grew from mid-20th-century reports of anticancer activity. Those reports did not survive scrutiny — the isolated lapachol showed unacceptable toxicity at effective doses in human trials, which is the outcome the traditional reputation obscures.
🧪 Theoretical / extrapolated benefits
- Popular in candida/gut-cleanse protocols — mechanistically plausible, clinically under-studied.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pau d'Arco actually does
The bark contains naphthoquinones, and the whole page turns on the fact that there are two of them and they are not the same molecule. Lapachol is a 2-hydroxy-3-prenyl-1,4-naphthoquinone — a para-quinone with a prenyl side chain. Beta-lapachone is a cyclized ortho-quinone formed from it. Almost every impressive claim made for pau d'arco belongs to the second, and the second is not what is abundant in the bark you can buy.
Beta-lapachone has one of the most elegant mechanisms in oncology pharmacology. NAD(P)H:quinone oxidoreductase 1 — NQO1 — normally protects a cell by performing a clean two-electron reduction of a quinone to a stable hydroquinone. With beta-lapachone the hydroquinone is unstable and immediately reoxidizes, so the enzyme is trapped in a futile redox cycle that burns NAD(P)H and floods the cell with hydrogen peroxide. NQO1 activity is the principal determinant of the cytotoxicity, and inhibiting NQO1 with dicoumarol protects the cell Pink 2000. The selectivity comes from NQO1 being over-expressed in many tumors — the enzyme meant to detoxify quinones becomes the thing that kills the cell.
Lapachol's own in-vivo chemistry is quieter and more consequential for a supplement buyer. A 1,4-naphthoquinone is a close structural relative of vitamin K, and the mechanism proposed for lapachol's effects in animals is vitamin K antagonism Maeda 2008. That single fact reorganizes the safety section below, because vitamin K antagonism is not antiplatelet activity: it impairs synthesis of clotting factors II, VII, IX and X, it shows up as a prolonged prothrombin time and a raised INR, and it is additive with warfarin specifically rather than with aspirin.
Cell, rodent, human — and where it stops
In cells. NQO1-transfected breast cancer lines; futile redox cycling; apoptosis; protection when NQO1 is inhibited Pink 2000.
In humans — and this is the part every pau d'arco page omits. Beta-lapachone did reach human trials, as the investigational agent ARQ 761, given to patients with pancreatic cancer as an NQO1-bioactivatable drug alongside chemotherapy Beg 2017. The molecule that works became a hospital drug with a companion biomarker, not a tea.
In mice, on the bark's own molecule, with a result nobody quotes. Oral lapachol was given to mice carrying B16BL6 melanoma. At 80–100 mg/kg it promoted metastasis; at 5–20 mg/kg it weakly suppressed it; the mechanism proposed for the promotion was vitamin K antagonism Maeda 2008. A dose-dependent reversal of direction, with the harm at the high end.
And there is an old oral toxicology record Morrison 1970, which is the sort of study that gets done before a compound is abandoned rather than after it succeeds.
The obstacle is the form, and it is total. The efficacy belongs to a purified ortho-quinone given to cancer patients under a biomarker-selected protocol Beg 2017. The product is a bark, prepared as a tea or a capsule, with no stated naphthoquinone content of either kind. There is no human trial of pau d'arco for candida, for immunity, or for anything else it is sold for.
Pau d'Arco — which form, and does it matter
Bark, species and part all move the chemistry. Several Tabebuia and Handroanthus species are traded as pau d'arco, and the naphthoquinones concentrate in the inner bark. Nothing on a shelf product states which species, which layer, or how much lapachol is present — and given that oral lapachol reversed direction between 20 and 80 mg/kg in mice Maeda 2008, an unstated content is a genuinely uncomfortable blank rather than a labeling nicety.
Tea and extract are pharmacologically different preparations. Lapachol is poorly soluble in water, so a decoction extracts relatively little of it while a hydroalcoholic extract extracts far more. The consequence is worth stating plainly: the traditional use record belongs to the tea, and it does not transfer to a concentrated extract capsule. A safety history built on a weak preparation is not a safety history for a strong one.
And the molecule with the good story is not what is on the shelf. Beta-lapachone is the one that was developed as a drug Beg 2017, and no supplement is standardized to a stated beta-lapachone content — so a buyer cannot tell how much of it they are getting, or whether they are getting any. If a product ever did state one, the NQO1 mechanism Pink 2000 would make it a compound requiring supervision rather than a tonic.
What would have to be true, and how you would know it was not
1. The most useful prediction on this page is a safety one, and it uses a test every clinic has. If lapachol acts as a vitamin K antagonist Maeda 2008, then a sufficiently large or prolonged intake should lengthen prothrombin time. Predict no measurable INR change at a cup of tea, and predict a measurable one at high-dose extract use. Predict, specifically, that anyone taking warfarin who adds pau d'arco sees an INR change within 3 to 7 days. Check INR at one week. Nobody publishes this, and it is the single most actionable sentence about this plant.
2. The prediction that cuts against the product. Predict no effect on any confirmed fungal endpoint — a positive culture, a documented recurrence rate — because there is no human trial and no evidence an oral dose reaches an antifungal concentration anywhere except transiently in the gut lumen.
3. The direction-of-dose prediction, offered as extrapolation from a mouse. The metastasis model reversed direction with dose Maeda 2008. If anything like that holds in people, then “more must be better” is not merely wrong here, it is the wrong sign. The conservative reading is that this is the one product on this shelf where the animal evidence argues for a ceiling rather than a floor.
What will fool you: the taste and the color. A dark, bitter, earthy tea reads as potent, and lapachol's poor water solubility means the strength of the brew is a poor guide to how much of the naphthoquinone is actually in the cup.
What nobody has tested yet
Nobody has measured plasma lapachol or beta-lapachone after a cup of tea or a capsule. One single-dose pharmacokinetic study would say whether any of the chemistry on this page is relevant to the product at all, and it has not been done.
Nobody has measured prothrombin time in humans taking pau d'arco. There is an animal mechanism predicting an effect Maeda 2008 and a test that costs almost nothing. Twenty people, an INR before and after four weeks, would generate the first human safety data this plant has.
The dose reversal has never been reproduced or explained. Promotion of metastasis at 80–100 mg/kg and weak suppression at 5–20 mg/kg Maeda 2008 is the single most important unresolved result about this bark, and it has sat unrepeated since 2008.
And there is no trial in candidiasis of any kind. Not a pilot, not a case series with confirmed cultures. The condition that sells this product has never been studied with it.
Pau d'Arco — its own safety story, not its category's
The bleeding mechanism is vitamin K antagonism, not antiplatelet activity, and getting that right changes what you do. The animal mechanism is interference with vitamin K Maeda 2008, which means the drug that matters most is warfarin, the test is INR rather than a platelet function assay, and dietary vitamin K becomes a variable. Product pages routinely file this under antiplatelet effects beside aspirin and clopidogrel; that framing points a reader at the wrong drug and the wrong test.
The dose-dependent harm signal is the reason to be conservative, and it is unique on this shelf. High oral doses promoted metastasis in a mouse melanoma model Maeda 2008. That is one study, in one model, unreplicated — and it is also the only oral efficacy study of the bark's principal molecule in a living animal. Anyone with a cancer history should weigh it before a course rather than after.
Tolerability is poor at doses that do anything. Nausea, vomiting and dizziness arrive at modest amounts, oral toxicology in animals is on record Morrison 1970, and the naphthoquinone that reached human trials did so as a purified investigational drug under supervision Beg 2017 rather than as something anyone swallowed at home.
Pregnancy: avoid, on documented toxicity rather than absence of data.
Who should not take it: anyone on warfarin or any anticoagulant, anyone within two weeks of surgery, anyone pregnant, and anyone with a cancer history. The honest summary of this page is that it is the one product in this cohort where the animal record contains a dose-dependent harm signal and the human record contains nothing at all — and that combination is a reason to leave it on the shelf.
Sources read for this page
- Pink JJ, et al. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. Journal of Biological Chemistry 2000 · PMID 10681517
- Beg MS, et al. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology 2017 · PMID 28346693
- Maeda M, et al. Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol. Toxicology and Applied Pharmacology 2008 · PMID 18294668
- Morrison RK, et al. Oral toxicology studies with lapachol. Toxicology and Applied Pharmacology 1970 · PMID 4989601
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: The symptom you actually have, named and counted — recurrent thrush, an itch, a rash — rather than 'candida', which is a self-diagnosis almost nobody has had confirmed. Write down the count per month before you start. If you cannot name a countable symptom, the honest answer to how you would know is that you would not.
- How long before it means anything: Short courses of two to four weeks with a written stop date. No human trial tells you what a course looks like, so the length is a convention rather than a finding, and an open-ended habit turns an unproven product into a permanent one.
- What will fool you: The die-off story. Feeling worse in the first days gets presented as proof the protocol is working, which makes the product impossible to fail: better means it worked and worse means it worked. Nothing that cannot fail can teach you anything. This bark's reputation also came from mid-century anticancer reports that did not survive testing. Recurrent thrush has real and diagnosable causes, including diabetes — that is a test, not a tea.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Pau d'Arco — safety & side effects
- Nausea, vomiting and dizziness at higher doses — it is poorly tolerated above modest amounts.
- Its bleeding interaction is vitamin K antagonism, not antiplatelet activity, and the difference decides which drugs matter. Lapachol, the naphthoquinone in the bark, is a vitamin K antagonist — the same mechanism warfarin uses. So this adds to warfarin and the other coumarins specifically. It is not the ginkgo or fish-oil interaction: it does not act on platelets alongside aspirin or clopidogrel, and it does not touch the factor Xa target that apixaban and rivaroxaban hit.
- It also decides which test to watch. An antiplatelet interaction is invisible to an INR; this one is not. If you take warfarin, tell whoever manages your INR before you start this and again if you stop, and expect a recheck either way. One nuance from the animal work: the vitamin K-dependent proteins do not fall together — protein C has the shortest half-life, so the first hours of a vitamin K antagonist can be pro-clotting rather than thinning. Neither direction is a good surprise on top of warfarin.
- Avoid in pregnancy — documented toxicity. The margin between traditional dose and toxic dose is narrower than for most botanicals, and the benefit evidence is weak. Not one we would reach for.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Pau d'Arco in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pau d'Arco
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | White cells and their differential — the actual immune measurement |
| Vitamin D (25-Hydroxy) | The deficiency with the most credible immune evidence |
| Zinc, Plasma | Real deficiency impairs immune function; excess doesn't help |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney, since 'detox' is what those two organs do |
The Frequent Illness & Immune Resilience panel covers these in one order — 8 markers, $97.65 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pau d'Arco — frequently asked questions
What is Pau d'Arco?
A South American bark traditionally used for antifungal (candida), immune and antimicrobial support.
What is the suggested dose of Pau d'Arco?
As directed (tea or extract), short courses. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Pau d'Arco dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Pau d'Arco?
Coach Cam sources Pau d'Arco from vetted, top-rated brands on iHerb — use the buy link on this page.
What Pau d'Arco is used for
Pau d'Arco appears under 1 goal in the goal router.
Related Immune & Detox supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.